DRP1 inhibition confers cardioprotection against doxorubicin while preserving anticancer efficacy
Yali Deng, Sebastian Bass-Stringer, Simon T. Bond, Jonathon Cross, Jia Quyen Truong, Leonardo M. Hugen, Hei-Yi H. Woo, Ayeshah Augusta Rosdah, Anne M. Kong, Christopher D. Hart, Kylie L. Gorringe, Rebecca Helen Ritchie, Sanij Elaine, Brian G. Drew, David W. Greening, , Shiang Yong Lim
This paper shows DRP1 inhibition reduces doxorubicin-induced cardiotoxicity while maintaining its anticancer effects in multiple cancer models.
bioRxiv · Feb 17, 2026 · PreprintPharmacology & Toxicology